Prils Market Analysis

  • Report ID: 4109
  • Published Date: Jul 25, 2024
  • Report Format: PDF, PPT

Prils Market Analysis

Application (Hypertension, Heart Failure, Chronic Kidney Disorder)

The hypertension segment is estimated to hold 50% share of the global prils market in the year 2036. The growth of the segment can be attributed to the increasing cases of hypertension across the globe. As more individuals with hypertension may need medications to control their blood pressure, this could lead to an increase in demand for market.

Besides prils are frequently combined with other antihypertensive drugs to improve blood pressure control which is further expected to contribute to the market growth. Around 970 million people worldwide, or over 25% of the population, have hypertension, and by 2025, that number is projected to rise by over 28%.

Distribution Channel (Hospital, Pharmacies)

Prils market from the hospital segment is expected to garner a significant share of 40% in the year 2036. Prils may be prescribed in hospitals for patients with comorbidities, such as diabetes or chronic renal disease that are frequently linked to hypertension or heart failure. They may be provided as part of the therapy plan for various comorbidities since many individuals admitted to hospitals may have several medical problems. As a result, the demand for prils in hospitals may be expanding along with the prevalence of these comorbidities. As a consequence, multiple opportunities for the segment's growth are expected in the next years.

Our in-depth analysis of the global prils market includes the following segments:

           Type

  • Amipril
  • Quinapril
  • Cilazapril
  • Benazepril

          Distribution Channel 

  • Hospital
  • Pharmacies

            Application

  • Hypertension
  • Heart Failure
  • Chronic Kidney Disorder
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4109
  • Published Date: Jul 25, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of prils is assessed at USD 2.25 Billion.

The prils market size was valued at USD 2.13 Billion in 2023 and is expected to reach USD 4.7 Billion by the end of 2036, expanding at around 6.3% CAGR during the forecast period i.e., between 2024-2036. Rising geriatric population and the growing incidences of cardiovascular diseases are the major factors driving the market growth

Europe is estimated to hold the second-largest share of 31% by 2036, driven by increasing initiatives to assist the expansion of generic medications through pricing and reimbursement in the region.

Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample